[177Lu]Lu-PSMA治疗中PSMA PET/CT肿瘤摄取与体积变化的临床影响
这项多中心回顾性研究纳入124例mCRPC患者,在[177Lu]Lu-PSMA治疗基线和2周期后行PSMA PET/CT,评估SUVmax、SUVmean、总肿瘤体积(TTV)变化及新病灶(NLs)与PSA-PFS和OS的关联。结果显示仅全身ΔTTV和NLs出现与更短PSA-PFS和OS显著相关,基于患者的ΔSUVmax和ΔSUVmean与结局无关。
要点
- 全身ΔTTV和出现新病灶与更短PSA-PFS和OS显著相关。
- 基于患者的ΔSUVmax和ΔSUVmean与结局无显著关联。
- 仅内脏病灶ΔSUVmax与PSA-PFS相关,与OS无关。
核心结论
- 仅ΔTTV和新病灶出现提供显著预后价值,评估[177Lu]Lu-PSMA治疗反应时应考虑。
研究设计与样本
- 多中心回顾性研究纳入2014至2019年接受[177Lu]Lu-PSMA的124例mCRPC患者,中位年龄73岁(四分位距67-76岁)。
- 基线和2周期治疗后行PSMA PET/CT,用qPSMA软件行全身分析SUVmax、SUVmean、TTV和新病灶。
主要发现
- 全身ΔTTV与更短PSA-PFS相关(HR 5.7,95%CI 3.59-9.06,P<0.0001),与更短OS相关(HR 2.3,95%CI 1.61-3.43,P<0.001)。
- 新病灶出现与更短PSA-PFS相关(HR 1.6,95%CI 1.4-1.8,P<0.0001),与更短OS相关(HR 1.3,95%CI 1.1-1.4,P<0.001)。
- 基于患者分析ΔSUVmax与结局无关(HR 1.00,95%CI 0.99-1.00,P=0.30),ΔSUVmean与结局无关(HR 0.90,95%CI 0.99-1.00,P=0.11)。
- 基于区域分析仅内脏病灶ΔSUVmax与PSA-PFS显著相关(P=0.007),与OS无关。
临床怎么用
- 评估[177Lu]Lu-PSMA治疗反应时,应重点关注全身总肿瘤体积变化和新病灶出现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although tumor volume and new lesions (NLs) have been investigated previously as measures of response, the clinical impact of changes in tumor uptake on prostate-specific membrane antigen (PSMA) PET remains largely unknown. Methods: This multicenter retrospective study investigated the clinical impact of changes in tumor uptake and volume on PSMA PET during [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer (mCRPC). The primary outcomes were the associations of changes in SUVmax (ΔSUVmax) and SUVmean (ΔSUVmean), changes in total tumor volume (ΔTTV), and occurrence of NLs with prostate-specific antigen (PSA) progression-free survival (PSA-PFS) and overall survival (OS). The study included patients with mCRPC who received [177Lu]Lu-PSMA between 2014 and 2019. PSMA PET/CT was performed at baseline and after 2 cycles of therapy. Whole-body analyses (SUVmax, SUVmean, TTV, and NLs) were performed and calculated using qPSMA software. Results: In total, 124 patients with mCRPC (median age, 73 y; interquartile range, 67-76 y) were included in the study. Whole-body ΔTTV and the occurrence of NLs were significantly associated with shorter PSA-PFS (hazard ratio [HR], 5.7; 95% CI, 3.59-9.06; and HR, 1.6; 95% CI, 1.4-1.8; P < 0.0001) and with OS (HR, 2.3; 95% CI, 1.61-3.43; and HR, 1.3; 95% CI, 1.1-1.4; P < 0.001). Patient-based analysis showed that ΔSUVmax and ΔSUVmean were not associated with outcome (HR, 1.00; 95% CI, 0.99-1.00; P = 0.30; and HR, 0.90; 95% CI, 0.99-1.00; P = 0.11). Region-based analysis found that only ΔSUVmax in visceral lesions was significantly associated with PSA-PFS (P = 0.007) but not with OS. Conclusion: Only ΔTTV and the occurrence of NLs provided significant prognostic value and should be considered when evaluating treatment response to [177Lu]Lu-PSMA therapy.
引用
- Djaileb L, Farolfi A, Rauscher I, et al. Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [177Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2026. PMID: 41167722. doi:10.2967/jnumed.125.270239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。